Antimicrobial resistance happens when microbes (such as bacteria, parasites, viruses or fungi) stop responding to the drugs designed to kill them.
The O’Neill report, commissioned by the UK government (published 2016) predicts that without action, AMR will cost $100 trillion in lost global production by 2050. This is twice the current annual global GDP.
The scale and urgency of the AMR problem is recognised as an international strategic priority by leading organisations worldwide. These include G20, World Health Organization, National Institute for Health Research (NIHR) and the National Health Service to list just a few.
The Liverpool approach
We’re leveraging our strengths in infectious diseases and global health research to tackle AMR in Liverpool. By initially concentrating on the health needs of those closest to us, we can create a model to expand our efforts to wider populations and other disease areas.
CEIDR is an interdisciplinary, connected organisation and our collaborative efforts will be key to effectively addressing AMR. The scope of the issue is so broad that pooling resources, in terms of the number of contributors and range of fields involved, is fundamental.
Tackling antimicrobial resistance requires a wide range of approaches and developing alternatives to antibiotics, in humans and animals, is critical to the fight. Vaccines have a vital role to play in combatting drug resistance, by preventing infections in the first place.
Professor Dame Sally Davies, UK Special Envoy on Antimicrobial Resistance.